Fluicell

Fluicell Accounts Payable

The Accounts Payable of Fluicell (FLUI.ST) as of Nov 20, 2026 is 1.30 M SEK. In the previous year, Accounts Payable was 897,000.00 SEK — a change of 45.26% (higher).

Accounts Payable

1.30 MSEK

YoY

45.26%

Last updated:

Accounts Payable of Fluicell is 2025 1.30 M SEK. Accounts Payable of Fluicell was 2024 897,000.00 SEK. It decreases by 45.26% higher compared to the previous year.

The Fluicell Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
854,000.00 SEK
Jan 1, 2019
1.87 M SEK
Jan 1, 2020
736,000.00 SEK
Jan 1, 2021
1.05 M SEK
Jan 1, 2022
858,000.00 SEK
Jan 1, 2023
1.50 M SEK
Jan 1, 2024
897,000.00 SEK
Jan 1, 2025
1.30 M SEK
The Fluicell Accounts Payable history
YEARAccounts PayableYoY
1.30 MSEK+45.26%
897,000.00SEK-40.36%
1.50 MSEK+75.29%
858,000.00SEK-18.05%
1.05 MSEK+42.26%
736,000.00SEK-60.58%
1.87 MSEK+118.62%
854,000.00SEK+12.52%
759,000.00SEK+235.84%
226,000.00SEK+289.66%
58,000.00SEK-63.08%
157,078.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Accounts Payable of Fluicell is 1.30 M SEK in 2025.

Accounts Payable of Fluicell changed from 897,000.00 SEK to 1.30 M SEK, representing a 45.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Fluicell since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fluicell

All Key Metrics — Fluicell